Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03879798 · ClinicalTrials.gov registry record · Phase 1
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03879798: Clinical Trial Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03879798 is a Phase 1 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03879798, a Phase 1 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will test the safety of the study drug, DS-3201b, given in combination with irinotecan to people who have recurrent small cell lung cancer (SCLC).
Interventions
- DRUG irinotecan
- DRUG DS-3201b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2023-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03879798
The ClinicalTrials.gov registry entry for NCT03879798 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which irinotecan is the first listed.
NCT03879798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03879798 about?
NCT03879798 is a clinical study titled "DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer". This study will test the safety of the study drug, DS-3201b, given in combination with irinotecan to people who have recurrent small cell lung cancer (SCLC).
What is the current status of trial NCT03879798?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-03-15. Estimated completion is 2023-05-02.
What interventions are being tested in trial NCT03879798?
The interventions under investigation include: irinotecan (DRUG), DS-3201b (DRUG).
Who is sponsoring clinical trial NCT03879798?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.